Our Mission

Biobide’s aim is to accelerate R&D process for Pharma, Biotech, Chemical, Cosmetic and Nutraceutical companies minimizing risks through our zebrafish services, adding value to clients R&D&i mainly in preclinical area.

We are a CRO specialized in zebrafish working under Good Laboratory Practice (GLP) and thanks to our automated and innovative tools, we have developed and validated time and cost effective Toxicity and Efficacy Assays, as well as disease models to be used in preclinical stages.

The followed strategy is based on:

Excellent services:

to develop, in an environment of Good Laboratory Practice, reliable and relevant assays for our Customers, Regulatory Bodies and, ultimately, for Human Health based on an experimental design and interpretation of results supported by a first-rate technology platform and innovative tools.

Expert team:

to integrate into our processes the capabilities required to understand and apply advances in genetic and physiological research, automation, image analysis and all other areas of knowledge which impact on our business model.

Global business:

having a network of alliances and strategic partnerships to develop and launch together new solutions to the market.


to achieve our Customers and Regulatory bodies being the promoters of our services.

Our History

Biobide was founded in 2005 in order to resolve the main problem that contemporary biotechnological and pharmaceutical companies were facing: how to deal with the low success rate in marketing new drugs and block busters. In 2014, the company was acquired by the Bionaturis Group, which is a biopharmaceutical company devoted to develop and manufacture biological drugs for human and animal health. The biotechnological group is listing on the Spanish stock exchange for SMEs (ticker BNT).

The group consists of 4 companies (Bionaturis, Biobide, ZIP Solutions and BNT Pacific LTD) and 2 subsidiaries (Biobide USA and BNT China Biosciences).

Biobide's Organization Chart

Victor Infante
President and CEO

Mr. Infante holds PhD in Science and Chemical degree. Appointed CEO and President of Bionaturis since 2005 and Managing Director of BNT Pacific Limited, and Chairman of Biobide Board of Directors.

José María Lozano

Mr. Lozano holds a degree in economics and business administration from Seville University and post-graduate studies in financial management and auditing and financial statements consolidation. Mr Lozano is Member of the Board of Biobide.

Andoni Cruz Pacheco
Co-founder and General Manager

Besides Biobide, Mr. Cruz is also co-founder of several ongoing companies, such as Imatec Innovación, GTCluster and Cyberclick. Mr. Cruz is Member of the Board of Biobide.

Arantza Muriana Miralles
Co-founder and R+D Management Director

Mrs. Muriana has the bachelor of Pharmacy and Master degree in R+D+i of New Drugs at the University of Navarra. In addition, she has a MBA from the San Pablo CEU University of Madrid and she is Member of the Board of Biobide.

Ainhoa Alzualde Zuloaga
Study Director

Ainhoa completed her PhD. in Physical Anthropology, Animal Physiology and Genetics. She is responsible of projects related to behavioral assays, ecotoxicity tests and organ specific toxicities as cardiotoxicity or muscle toxicity among others.

Celia Quevedo Soubriet
Study Director

Celia took a PhD. in Biochemistry and Molecular Biology after studying the regulation of protein initiation factors in neurons. She manages different projects related with development of models, as well as some general and organ specific toxicities such as teratogenicity or ototoxicity.

Virginia Caballero
Study Director

Virginia completed her PhD. in Toxicology and Pharmacology. She is responsible of cosmetic line projects related to the evaluation of the toxicity and efficacy assays. She also manages immunotoxicity and immunocompetence as well as infectious disease projects.


    Why use zebrafish as an alternative to mammalian species?

    • High genetic homology with humans (> 85%) Cardiovascular, nervous and digestive systems similar to those of mammals.

    • High productivity: 100-300 eggs/ mature female/ mating.

    • Small size Maintenance costs considerably lower than those for mammals.

    • Fast development and external organogenesis entire body plan established by 24 hpf and most of internal organs totally developed by 96 hpf.

    • Transparent embryos. Organs, cells, and tissues are visualized in vivo and investigated in realtime.

    • Easily manipulated using well establish genetic and molecular approaches.

    • Small quantity of test compounds are needed. Addition directly to the embryo media.

    • Use of fluorescent zebrafish allows automation of assays to HCS levels.

    • Cost and time efficiency compared with other animal models.


    Biobide has developed a fully automated platform to reproduce the manual process of screening in a 96-well plate format 'in vivo' with zebrafish embryos.

    The zebrafish model can be adapted to HCS PLATFORMS allowing:

    • Higher analysis capacity: more compounds tested in less time.

    • Higher speed: the higher analysis capacity shortens necessary testing times, with zebrafish embryos.

    • More relevant information to be provided: the automated High Content Screening in zebrafish ('in vivo') gives more information than 'in vitro' screenings, because the study is based on an organism rather than on an isolated cell.


    The Biobide Zebrafish Facility can house more than 80.000 fish. Our highly qualified human team takes care of the fish with the rigorous health and welfare standards essential for our assays. With more than 35 diferent lines, some of them generated in house, Biobide’s Zebrafish Facility has the capability of providing fish to the laboratory to develop our client assays.